Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Humacyte Inc’s stock clocked out at $3.75, down -4.09% from its previous closing price of $3.91. In other words, the price has decreased by -$4.09 from its previous closing price. On the day, 2.05 million shares were traded.
Ratios:
To gain a deeper understanding of HUMA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, Reiterated its Buy rating but revised its target price to $15 from $12 previously.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.
Piper Sandler Upgraded its Underweight to Neutral on August 14, 2023, whereas the target price for the stock was revised from $2.75 to $3.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’24 when Constantino Michael T. bought 4,600 shares for $4.39 per share. The transaction valued at 20,181 led to the insider holds 16,950 shares of the business.
Niklason Laura E bought 1,797 shares of HUMA for $7,979 on Nov 19 ’24. The President, CEO and Director now owns 243,851 shares after completing the transaction at $4.44 per share. On Nov 19 ’24, another insider, Dougan Brady W, who serves as the Director of the company, bought 1,797 shares for $4.44 each. As a result, the insider paid 7,979 and bolstered with 243,851 shares of the company.
Stock Price History:
Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $2.81. The 50-Day Moving Average of the stock is -15.61%, while the 200-Day Moving Average is calculated to be -33.64%.
Shares Statistics:
A total of 119.84M shares are outstanding, with a floating share count of 104.38M. Insiders hold about 18.88% of the company’s shares, while institutions hold 33.11% stake in the company.
Earnings Estimates
Humacyte Inc (HUMA) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.24 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.99 and -$1.4 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.87, with 4.0 analysts recommending between -$0.68 and -$1.03.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $9.53M in the next fiscal year. The high estimate is $20.4M and the low estimate is $2.74M.
